10
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Effects of Estrogen-Induced Hyperprolactinemia on Endocrine and Sexual Functions in Adult Male Rats

      research-article

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Chronic estrogen treatment can lead to development of prolactin (PRL) secreting pituitary tumors. We have tested the ability of diethylstilbestrol (DES) to produce persistent hyperprolactinemia (hyperPRL) in adult male rats and examined the effects of this treatment on hypothalamic-pituitary-testicular function, adenohypophyseal structure, copulatory behavior and fertility. Silastic capsules containing approximately 5 mg DES were subcutaneously implanted into adult male CDP (F-344)/CrlBR rats and removed 15 or 20 weeks later. Extreme hyperPRL, as well as suppression of plasma LH and FSH levels, persisted after DES capsules were removed. In contrast, plasma testosterone levels increased rapidly after removal of DES capsules and reached normal levels within 4–6 weeks. Copulatory behavior was assessed on two occasions between 7 and 14 weeks after removal of the DES capsules and was found to be suppressed in DES-treated rats, as evidenced by significant increases in latencies to mount, to intromit and to ejaculate. Moreover, when the animals were placed with normal females, the interval until conception was significantly greater in DES-treated than in control males. In spite of these differences in copulatory behavior, 10 of 11 DES-treated males were fertile. At autopsy, 44 weeks after capsule implantation (i.e. 24 or 29 weeks after capsule removal), DES-treated rats had marked enlargement of the anterior pituitary, increased weights of the lateral prostate and the adrenals, increased levels of testicular hCG-binding sites, reduced concentration of dopamine and norepinephrine in the median eminence and increased concentration of LHRHin the preoptic area. DES-treated and control rats did not differ with respect to relative weights of the testes, ventral prostate and seminal vesicles and testicular testosterone production in vitro in the presence and in the absence of hCG. Immunocytochemical studies oí the adenohypophysis in a separate group of similarly treated animals revealed marked increases in the total number of parenchymal cells and in the relative proportion of mammotrophs. We conclude that chronic exposure of adult male CDF (F-344) rats to DES resulted in persistent massive mammotroph hyperplasia and that the resulting 20- to 100-fold elevation of peripheral PRL levels in these animals had little, if any, suppressive effect on testicular function, in spite of the drastic reduction in peripheral LH levels.

          Related collections

          Author and article information

          Journal
          NEN
          Neuroendocrinology
          10.1159/issn.0028-3835
          Neuroendocrinology
          S. Karger AG
          0028-3835
          1423-0194
          1984
          1984
          28 March 2008
          : 39
          : 2
          : 126-135
          Affiliations
          aDepartments of Obstetrics and Gynecology and Anatomy, University of Texas Health Science Center at San Antonio, San Antonio, Tex.; bDepartment of Physiology, University of Pittsburgh School of Medicine, Pittsburgh, Penn., and cDepartment of Biochemistry and Biophysics, Pennsylvania State University, College Park, Penn., USA
          Article
          123968 Neuroendocrinology 1984;39:126–135
          10.1159/000123968
          6382042
          21e8410b-f46f-4741-9bed-741db0bbac3a
          © 1984 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          History
          : 29 September 1983
          : 11 January 1984
          Page count
          Pages: 10
          Categories
          Original Paper

          Endocrinology & Diabetes,Neurology,Nutrition & Dietetics,Sexual medicine,Internal medicine,Pharmacology & Pharmaceutical medicine
          Brain neurotransmitters,Gonadotropins,Hyperprolactinemia,Fertility,Testosterone,Copulatory behavior

          Comments

          Comment on this article